Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1182 - Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small-cell lung cancer patients


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Teppei Sugano


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


T. Sugano1, M. Seike1, Y. Saito1, N. Takano1, K. Hisakane1, S. Takahashi1, T. Tanaka1, T. Kashiwada1, S. Nakamichi1, S. Takeuchi1, A. Miyanaga1, Y. Minegishi1, R. Noro2, K. Kubota2, A. Gemma2

Author affiliations

  • 1 Department Of Pulmonary Medicine And Oncology, Graduate School Of Medicine, Nippon Medical School, 1138603 - Tokyo/JP
  • 2 Department Of Pulmonary Medicine And Oncology, Graduate School Of Medicine, Nippon Medical School, Tokyo/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1182


Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD associates with treatment efficacy and to research the characteristics of ILD in advanced non-small-cell lung cancer (NSCLC).


Between December 2015 and November 2018, 132 advanced NSCLC patients were treated with nivolumab, pembrolizumab or atezolizumab. The patients were categorized into two groups (irAEs group or non-irAEs group). Subsequently, we extracted patients based on the incidence of ILD (ILD group). Treatment efficacy and characteristics of ILD were evaluated in each group.


The 39 (30%) patients developed irAEs. ILD was observed in 16 (12%) patients. Patients with ILD had significantly higher objective response rate (ORR) compared with irAEs-non-ILD patients and non-irAEs patients (63%, 43% and 22%, respectively). Median progression-free survival (mPFS) was 15.9 months in the ILD patients, 5.4 months in the irAEs-non-ILD patients and 3.3 months in the non-irAEs patients (Log rank, P = 0.035). Pre-existing interstitial pneumonia (IP) was an independent risk factor of ILD-induced ICIs (odds ratios 15.1; 95% CI: 2.23-102, P = 0.005).


ORR and PFS were significantly better in the ILD patients than in the irAEs-non-ILD and non-irAEs patients. Pre-existing history of IP was an independent risk factor of ILD-induced ICIs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.